Rights offering (paid-in capital increase) decision (subsidiary)

A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-08-20) →

What happened

Rights Offering Decision (Subsidiary's Material Management Matter) Report on a Material Management Matter of the Subsidiary Lotte Biologics Co., Ltd.

1. Type and number of new shares Common shares: 4,209,000 Other share classes: -

2. Par value per share (KRW): 5,000

3. Total shares issued before the capital increase Common shares: 18,292,169 Other share classes: -

4. Purpose of fundraising Facility funds (KRW): 255,309,522,000 Funds to acquire business: - Working capital: - Debt repayment funds: - Funds to acquire securities of other companies: - Other funds: -

5. Method of capital increase: Shareholder-allotment rights offering

[For a shareholder-allotment rights offering] 6. New share issue price Confirmed issue price, common shares (KRW): 60,658 Other share classes (KRW): - Expected issue price, common shares (KRW): -, expected confirmation date: - Other share classes (KRW): -, expected confirmation date: -

7. Method of determining the issue price: Valuation by an external appraiser

8. New-share allotment record date: 2026-07-20

9. New shares allotted per existing share: 0.2300985

10. Preferential allotment ratio for employee stock ownership association members (%): -

11. Expected subscription dates Employee stock ownership association: start date -, end date - Existing shareholders: start date 2026-08-19, end date 2026-08-19

12. Payment date: 2026-08-19

13. Treatment plan for forfeited/odd-lot shares: Forfeited shares and odd lots arising from the existing shareholders' subscription will not be issued

14. New shares' dividend start date: 2026-01-01

15. Expected date of delivery of new share certificates: -

16. Lead underwriter (if not a direct public offering): -

17. Whether new-share subscription rights are transferable: Not applicable

18. Board resolution date: 2026-07-03 - Outside directors present: -, absent: - - Attendance of the auditor (audit committee member who is not an outside director): Present

19. Whether a securities registration statement must be filed: No

20. If exempted from filing, the reason: This does not constitute a public offering under Article 9, Paragraph 7 of the Financial Investment Services and Capital Markets Act, and the subsidiary is an unlisted company whose shares have never previously been publicly offered or sold.

21. Whether subject to Fair Trade Commission reporting: No

22. Other matters important for investment decisions - This disclosure concerns a material management matter of Lotte Biologics Co., Ltd., a subsidiary of Lotte Corporation, which decided to raise capital through a rights offering to fund construction of its No. 1 plant at the Songdo bio campus. - This is a shareholder-allotment rights offering; forfeited shares and odd lots may arise depending on the subscription results of existing shareholders, and such forfeited shares and odd lots will not be issued. As a result, the number of new shares issued and the amount raised may change. - "3. Total shares issued before the capital increase" above is the total number of shares issued by Lotte Biologics Co., Ltd. as of the date of its rights-offering decision (July 3, 2026). - "6. New share issue price" above was determined by an external appraiser's valuation as of the end of March 2026. - "15. Expected date of delivery of new share certificates" is left blank because Lotte Biologics Co., Ltd. does not issue physical share certificates. - "18. Board resolution date" above is the date of the board resolution of Lotte Biologics Co., Ltd. - "21. Whether subject to Fair Trade Commission reporting" above may change depending on the subscription results of existing shareholders (related parties), etc. - The above schedule and details may change depending on the progress of Lotte Biologics Co., Ltd.'s rights offering. - In the "Matters Concerning the Subsidiary" section below, the subsidiary's total assets and the parent company's consolidated total assets are based on the consolidated financial statements as of the end of 2025.

Related disclosures: -

[Matters Concerning the Subsidiary] Subsidiary name: Lotte Biologics Co., Ltd. (English: LOTTE BIOLOGICS Co., Ltd.) - Representatives: James Park, Shin Yu-yeol - Principal business: Biopharmaceutical contract manufacturing - Whether a major subsidiary: Not applicable Subsidiary's total assets (KRW): 1,979,933,424,978 Parent's consolidated total assets (KRW): 23,071,072,297,336 As a percentage of the parent's consolidated total assets (%): 8.58